Data / Drug companies / Fenofibric acid
Fenofibric acid: 7 companies and 14 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Fenofibric acid is listed in the FDA National Drug Code Directory by 7 companies, with 14 products in commercial distribution. 14 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, delayed release, and the newest product started marketing on June 1, 2024.
The request: Get every company that lists fenofibric acid in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 7
- Products
- 14
- Generic (ANDA) products
- 14 (100.0%)
- Application numbers
- 6
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list fenofibric acid
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alembic Pharmaceuticals Inc. | 2 | capsule, delayed release | Generic drugs (ANDA) | May 15, 2017 |
| Alembic Pharmaceuticals Limited | 2 | capsule, delayed release | Generic drugs (ANDA) | May 18, 2017 |
| Amneal Pharmaceuticals of New York LLC | 2 | capsule, delayed release | Generic drugs (ANDA) | June 1, 2024 |
| Aurobindo Pharma Limited | 2 | capsule, delayed release | Generic drugs (ANDA) | July 25, 2019 |
| Leading Pharma, LLC | 2 | capsule, delayed release | Generic drugs (ANDA) | July 18, 2019 |
| Lupin Pharmaceuticals, Inc. | 2 | capsule, delayed release | Generic drugs (ANDA) | December 4, 2013 |
| Macleods Pharmaceuticals Limited | 2 | capsule, delayed release | Generic drugs (ANDA) | February 26, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, delayed release | 14 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Peroxisome Proliferator Receptor alpha Agonist | 14 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.